Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema ...
Pharvaris N.V. (NASDAQ: PHVS) is a biotechnology company focused on addressing significant unmet needs in rare diseases driven by bradykinin biology. The company concentrates on the development and (planned) commercialization of oral therapies targeting the bradykinin B2 receptor. Its lead investigational product, deucrictibant, is designed as a small-molecule antagonist to help treat attacks and, in clinical programs, to support prophylaxis to reduce the frequency and severity of hereditary angioedema (HAE) attacks. Pharvaris is also pursuing clinical development in related bradykinin-mediated conditions such as acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH).
From a business perspective, Pharvaris positions itself in the late-stage segment of biopharma, where capital efficiency, clinical execution, and regulatory milestones are central to value creation. The company’s focus on an oral mechanism and disease area with high medical need aims to differentiate therapy convenience and potential adherence advantages versus more traditional approaches that may be injectable or require complex administration pathways.
In terms of products and services, Pharvaris primarily conducts pharmaceutical R&D—progressing a pipeline from formulation and clinical trials toward potential commercialization. The company is developing extended-release and immediate-release oral formulations of deucrictibant, aligning product development with the therapeutic goals of on-demand treatment and longer-term prevention strategies. These formulation efforts are often critical for usability, pharmacokinetic characteristics, and clinical outcomes.
With respect to costs and financial characteristics, the company’s valuation and operating metrics (as reflected in available market/TTM financial ratios) suggest a typical late-stage biotech profile: significant investment and expenditures in development activities, with profitability not yet reflected in margins. The provided financial snapshot indicates negative returns on assets/equity and negative earnings/free cash flow yield measures, consistent with R&D-intensive operations prior to sustained product revenue.
Key leadership includes CEO and co-founder Berndt Modig. The company is headquartered in Zug, Switzerland, and was incorporated in 2015, reflecting an organizational timeline that is relatively young but aligned with the long clinical development cycles typical for rare-disease programs. Headline operational scale is in the ~100–200 employee range (129 reported), consistent with a focused team supporting clinical operations, regulatory activities, and drug-development functions.
Overall, Pharvaris’ strategic “wish” is to bring an effective oral bradykinin B2 antagonist to patients with HAE and related conditions, achieving clinical endpoints and regulatory approval to transition from development toward commercialization. Success would likely depend on robust phase 3 outcomes across indications (treatment and prophylaxis), efficient formulation execution, and the ability to fund and de-risk further commercialization readiness.
CDMO A — Deucrictibant API Manufacturer (Primary)CDMO B — Deucrictibant API Manufacturer (Secondary)CDMO C — PHVS416 Drug Product Manufacturer (IR Capsule)CDMO D — PHVS719 Drug Product Manufacturer (ER Tablet)Raw Material / Fine Chemical Suppliers (API Precursors)Excipient & Capsule/Tablet Material Suppliers
Downstream
3
HAE Patients (Target End-User Population)U.S. Specialty Pharmacy Network (To Be Established)Healthcare Provider / HAE Treatment Centers
